Sunday 18 October 2026
Export OBIO’s income statement to Excel — free account
Orchestra BioMed Holdings, Inc.
OBIO Healthcare Biotechnology
Orchestra BioMed Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $33.5 million, up 1,169.2% from fiscal 2024. In the quarter to June 2026, revenue fell 89.5%, EPS grew 24.0%, free cash flow fell 25.9% and total debt rose 142.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
5.45
0.29
−5.05%
Follow OBIO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
4 | 6 | 6 | 5 |
| (166.97%) | (122.40%) | (189.00%) | (607.32%) | ||
| (83.39%) | (55.44%) | (68.69%) | (75.16%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(95.42%) | (57.01%) | (65.02%) | (59.68%) | |
Average Days of Receivables |
6.74 | 1.04 | 0.94 | 0.58 | |
Free Cash Flow per Share |
(1.16) | (1.04) | (0.88) | (0.93) | |
Free Cash Flow |
(60.79) | (49.45) | (55.08) | (59.10) | |
Capital Expenditures |
(0.56) | (0.49) | (0.56) | (0.78) | |
| Other line items | |||||
Cash ROIC |
(39.54%) | (28.36%) | (36.74%) | (36.01%) | |
Accounts Receivable Turnover |
33.75 | 358.10 | 378.31 | 477.25 | |
Accounts Payable Turnover |
0.03 | 0.03 | 0.03 | 0.03 | |
Inventory Turnover |
0.66 | 0.79 | 0.86 | 0.72 | |
Average Days of Payables |
15,698.71 | 11,708.82 | 12,945.20 | 14,255.92 | |
Days of Inventory on Hand |
676.27 | 595.53 | 568.01 | 581.21 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1,857.10% | 173.78% | 184.83% | 197.71% | |
Selling, General and Administrative Expense of Revenue |
905.82% | 80.38% | 82.58% | 83.15% | |
Share Based Compensation of Revenue |
430.45% | 35.77% | 36.25% | 34.77% | |
Operating CF/Net income |
0.80 | 0.92 | 0.99 | 0.98 | |
Depreciation/Fixed assets |
0.32 | 0.32 | 0.31 | 0.29 | |
Capex/Depreciation |
(1.10) | (0.90) | (0.99) | (1.30) | |
Revenue per Share |
0.05 | 0.70 | 0.52 | 0.50 | |
Operating CF per Share |
(1.15) | (1.03) | (0.87) | (0.91) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Capex to Sales |
0.20 | 0.01 | 0.02 | 0.02 |
Columns are period end dates